SecBot SecBot
144 ·Filed Nov 5, 2026

VCEL

Vericel Corp
NEUTRAL
Impact 2/10
Horizondays Processed11d 10h ago SEC0001959173-26-007797
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

The sale is small and routine for a director. Monitor for any follow-on sales or insider selling patterns, but this filing alone does not signal a change in company outlook.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$54.62
T+0 close · Nov 5, 2026 · via day close
Latest settled
+4.28%
T+5 · $56.96 · next T+20 in 20d
Vs SPY
+1.69%
α at T+5
Latest observation
+6.59%
T+6 · FF3 residual α
  1. T+0 · Nov 6 $54.62entry
  2. T+1 · 8d ago +6.90%α +4.54% · $58.39
  3. T+5 · 4d ago +4.28%α +1.69% · $56.96
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director Robert L. Zerbe filed a Form 144 notice of intent to sell 3,000 shares of Vericel Corp common stock, with an estimated aggregate market value of $156,682. The shares were acquired via a stock option exercise on the same day. This is a relatively small sale relative to the company's $2.1B market cap and the insider's likely holdings, and is routine for a director.

Key Facts

  • Insider: Robert L. Zerbe, MD, Director of Vericel Corp
  • Proposed sale: 3,000 shares of common stock
  • Estimated aggregate market value: $156,682.29
  • Shares acquired via stock option exercise on 11/05/2026
  • Broker: Fidelity Brokerage Services LLC
  • Filing date: 2026-11-05

Financial Impact

Sale of 3,000 shares valued at ~$156,682, representing less than 0.01% of the company's $2.1B market cap

dilution

Risk Factors

  • Form 144 is an intent to sell; the actual sale may not occur
  • Insider selling could increase if additional shares are sold in the future

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001959173-26-007797
Document: 0001959173-26-007797-index.html0001959173-26-007797
Document: 0001959173-26-007797.txt0001959173-26-007797

Track record

30 reports on VCEL

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +31.08% at T+60 after the May 7, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 13, 20263d ago 144 Neutral 2/10 Entry $56.96 Now $57.48 +0.91% settles Feb 11
  2. Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.96 Now $57.48 +0.91% settles Feb 11
  3. Nov 12, 20264d ago 144 Neutral 1/10 Entry $57.42 Now $57.48 +0.10% settles Feb 10
  4. Nov 10, 20266d ago 144 Neutral 2/10 Entry $59.03 Now $57.48 −2.63% settles Feb 8
  5. Nov 9, 20267d ago 144 Neutral 2/10 Entry $59.03 Now $57.48 −2.63% settles Feb 8
  6. Nov 9, 20267d ago 144 Neutral 3/10 Entry $59.03 Now $57.48 −2.63% settles Feb 8
  7. Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $59.03 Now $57.48 −2.63% settles Feb 8
  8. Nov 6, 202610d ago 144 Neutral 2/10 Entry $58.39 Now $57.48 −1.56% settles Feb 5
  9. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $58.39 Now $57.48 −1.56% settles Feb 5
  10. Nov 5, 202611d ago 144 Neutral 2/10 Entry $54.62 Now $57.48 +5.24% settles Feb 4
Showing 10 of 30

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026